Generic Name and Formulations:
Luliconazole 1%; cream.
Bausch Health Companies Inc.
Indications for LUZU:
Interdigital tinea pedis, t. cruris, and t. corporis caused by Trichophyton rubrum and Epidermophyton floccosum.
Adults and Children:
Apply to affected area and approximately 1 inch of the immediate surrounding area(s) once daily. T. corporis (≥2yrs): treat for 1 week. T. pedis (≥12yrs): treat for 2 weeks. T. cruris (≥12yrs): treat for 1 week.
Not for ophthalmic, oral, or intravaginal use. Pregnancy. Nursing mothers.
May inhibit CYP2C19 activity.
Application site reactions.
Endocrinology Advisor Articles
- Diabetic Retinopathy Risk Not Increased With GLP-1 Receptor Agonist Use in T2D
- Concurrent Risk Factors and Microvascular Complications in Type 1 Diabetes
- Higher Risk for Meningioma Linked to GH Treatment, Radiotherapy During Childhood
- Early Treatment Intensification and Faster Glycemic Control in T2D
- Comparing Antidiabetic Drug Classes for Risk of Heart Failure
- Nutraceuticals May Benefit Patients Who Are Statin Intolerant
- Hypertension Treatments: ARBs
- Semaglutide vs Liraglutide for Weight Loss in Patients With Obesity
- Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes
- Thyroid Hormone Levels, Body Composition, Insulin Resistance in Euthyroid Patients
- Behavioral Weight Loss Interventions May Prevent Obesity
- Disaster Preparedness 101: Physician Resources for Patients
- Assessing the Environmental Impact of the Healthcare Industry
- Medical Schools Phase Out Lectures as Education Shifts Outside the Classroom
- Clonidine Testing Is Safe and Reliable for Diagnosing Growth Hormone Deficiency